Anterix Inc.
74.90USD
+1.7400 (+2.38%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on ATEX.
Revenue
| (USD) | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| FY | 1.9M | 4.2M | 6.0M | 6.5M | 20.8M | 17.8M |
| Q1 | 335.0K | 608.0K | 1.5M | 1.4M | 2.0M | — |
| Q2 | 398.0K | 1.1M | 1.6M | 1.6M | 2.0M | — |
| Q3 | 578.0K | 1.3M | 1.6M | 1.6M | 2.0M | — |
| Q4 | 608.0K* | 1.3M* | 1.4M* | 2.0M* | — | — |
Revenue
| (USD) | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| FY | -.870 | -.490 | -.610 | 4.83 | -1.11 | -.591 |
| Q1 | -.710 | -.110 | -.840 | 1.35 | .010 | — |
| Q2 | -.560 | .110 | -.690 | 2.86 | -.283 | — |
| Q3 | -.420 | .020 | .410 | -.350 | -.215 | — |
| Q4 | .825* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
Revenue to net income
| -.502* |
| .496* |
| .987* |
| — |
| — |
Debt level and coverage